Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's growth and performance during the specified Class Period [1][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company specializing in cataract treatment, with its main product being the RxSight Light Adjustable Lens system, which includes an intraocular light adjustable lens and a light delivery device [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight and its executives misrepresented the company's growth, stating that utilization was rising and that newer customer cohorts were adopting the technology at a comparable or faster rate than previous cohorts. In reality, the company faced challenges with its field organization, leading to slower adoption and declining utilization [4]. - The lawsuit highlights that incremental placements of light delivery devices did not result in the expected volume of lens procedures, undermining the company's growth model [4]. Impact of Disclosures - On April 2, 2025, RxSight reported a sequential decline in quarterly lens sales and reduced its full-year revenue guidance by approximately $24 million, resulting in a 38% drop in the stock price [5]. - Further disclosures on July 8, 2025, revealed a 45% sequential decline in light delivery device sales and a second consecutive quarter of declining lens sales, leading to another 38% decrease in stock price [6]. Legal Representation - The plaintiffs in the lawsuit are represented by Robbins Geller Rudman & Dowd LLP, a law firm with significant experience in prosecuting investor class actions related to financial fraud [7].

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens® (LAL®/LAL+®) and the RxSight Light Delivery Device (LDD™), representing the first and only commercially available intraocular lens (IOL) technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Morgan Stanley Healthcare Conference in New York City on September 8, 2025, at 7:45 a.m. Pacific Time / 10:45 a.m. Eastern Time [2] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Wells Fargo Healthcare Conference in Boston on September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time [2] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients after cataract surgery [3] - The company offers the RxSight Light Adjustable Lens system, which includes the RxSight Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Upcoming Events - RxSight's management is scheduled to present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time [2] - A live and archived webcast of the presentation will be accessible for interested parties [2] Contact Information - Shelley B. Thunen serves as the Chief Financial Officer and can be contacted via email at sthunen@rxsight.com [4] - Oliver Moravcevic is the VP of Investor Relations and can be reached at omoravcevic@rxsight.com [4]